ArticleTrials2025

POINTER: study protocol for a phase 2b, randomised, placebo-controlled, double-blind, parallel group dose-finding clinical study to evaluate the efficacy of RMC-035 on renal function and safety, in participants at high risk for kidney injury, following open-chest cardiac surgery.

Alexander Zarbock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.